Q2 2024 Earnings Forecast for TG Therapeutics, Inc. Issued By B. Riley (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at B. Riley lifted their Q2 2024 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Wednesday, May 1st. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn ($0.04) per share for the quarter, up from their previous forecast of ($0.05). B. Riley currently has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.11) per share. B. Riley also issued estimates for TG Therapeutics’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.04 EPS and FY2024 earnings at ($0.10) EPS.

A number of other equities research analysts have also issued reports on the stock. The Goldman Sachs Group upped their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. LADENBURG THALM/SH SH upped their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. StockNews.com lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. Finally, HC Wainwright lifted their price objective on TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.83.

TG Therapeutics Stock Down 1.4 %

Shares of TGTX opened at $16.19 on Monday. The stock has a 50 day moving average price of $15.25 and a 200 day moving average price of $14.46. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 70.39 and a beta of 2.33.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. TG Therapeutics’s revenue was up 713.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.28) EPS.

Insider Activity

In related news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of TG Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pingora Partners LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter valued at about $27,000. PNC Financial Services Group Inc. boosted its position in shares of TG Therapeutics by 131.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares during the period. NBC Securities Inc. purchased a new position in shares of TG Therapeutics during the 3rd quarter worth approximately $58,000. Anchor Investment Management LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $80,000. Finally, REDW Wealth LLC purchased a new stake in TG Therapeutics in the third quarter valued at approximately $84,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.